Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
A benefit for balstilimab in cervical cancer irrespective of PD-L1 expression gives Agenus a shot at US approval.